TDP-43 Pathology in Corticobasal Syndrome [TDP-43](/diseases/tdp-43-proteinopathy) pathology is a key pathological finding in [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS), present in approximately 40-50% of cases. This proteinopathy, characterized by cytoplasmic inclusions of the TDP-43 protein, represents a major pathological substrate underlying CBS and has significant implications for diagnosis, prognosis, and therapeutic development.
Prevalence and Classification
Pathological Subtypes in CBS CBS demonstrates remarkable pathological heterogeneity. Based on autopsy studies:
| Pathological Subtype | Prevalence | Key Features |Tau-predominant (4R tau) | 50-55% | CBD-type tau pathology, astrocytic plaques |TDP-43 predominant | 25-35% | Motor neuron disease-type inclusions |Alzheimer's disease comorbidity | 15-20% | Aβ plaques, tau NFTs |α-Synuclein comorbidity | 5-10% | Lewy bodies |Mixed pathology | 10-15% | Multiple proteinopathies |
TDP-43 Subtype Characteristics The TDP-43 predominant subgroup represents a distinct pathological entity:
Neuronal cytoplasmic inclusions : Ubiquitin-positive, TDP-43 positiveNeuronal intranuclear inclusions : Less common but specific dystrophic neurites : In affected regionsLimited tau pathology : May show minimal 4R tau involvementNeuropathological Features
Regional Distribution TDP-43 pathology in CBS shows characteristic patterns:
...
TDP-43 Pathology in Corticobasal Syndrome [TDP-43](/diseases/tdp-43-proteinopathy) pathology is a key pathological finding in [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS), present in approximately 40-50% of cases. This proteinopathy, characterized by cytoplasmic inclusions of the TDP-43 protein, represents a major pathological substrate underlying CBS and has significant implications for diagnosis, prognosis, and therapeutic development.
Prevalence and Classification
Pathological Subtypes in CBS CBS demonstrates remarkable pathological heterogeneity. Based on autopsy studies:
| Pathological Subtype | Prevalence | Key Features |Tau-predominant (4R tau) | 50-55% | CBD-type tau pathology, astrocytic plaques |TDP-43 predominant | 25-35% | Motor neuron disease-type inclusions |Alzheimer's disease comorbidity | 15-20% | Aβ plaques, tau NFTs |α-Synuclein comorbidity | 5-10% | Lewy bodies |Mixed pathology | 10-15% | Multiple proteinopathies |
TDP-43 Subtype Characteristics The TDP-43 predominant subgroup represents a distinct pathological entity:
Neuronal cytoplasmic inclusions : Ubiquitin-positive, TDP-43 positiveNeuronal intranuclear inclusions : Less common but specific dystrophic neurites : In affected regionsLimited tau pathology : May show minimal 4R tau involvementNeuropathological Features
Regional Distribution TDP-43 pathology in CBS shows characteristic patterns:
Motor Cortex (BA4, BA6)Highest burden
Correlates with cortical signs (apraxia, alien limb)
Premotor and Supplementary Motor Areas Significant involvement
Associated with motor planning deficits
Posterior Parietal Cortex Variable involvement
Correlates with spatial processing deficits
Basal Ganglia Moderate involvement
Contributes to movement disorders
Brainstem and Spinal Cord Variable involvement
May show involvement of corticospinal tracts
Morphological Features
Mermaid diagram (expand to render)
Comparison with Other TDP-43 Diseases | Disease | TDP-43 Burden | Regional Pattern | Inclusions Type |CBS | Moderate-high | Frontoparietal > motor | NCI > NII |ALS | High | Motor cortex, spinal cord | NCI dominant |FTLD-TDP | High | Frontal, temporal | NCI, NII, DN |CBD | Low-moderate | Variable | Usually minimal |
Genetic Associations
Causative Mutations
GRN Gene Mutations
Prevalence : 5-10% of CBS casesMechanism : Progranulin haploinsufficiencyInheritance : Autosomal dominantOnset : Earlier (55-65 years)C9orf72 Repeat Expansions
Prevalence : 2-5% of CBS casesMechanism : Hexanucleotide repeat expansionDPR toxicity : Bidirectional translation productsPhenotype : Often with ALS/FTD featuresRisk Factors
TMEM106B
Risk allele : rs1991730 (G allele)Effect : Modulates TDP-43 pathologyPopulation frequency : ~40%Other Genetic Modifiers
VCP mutations : Rare but describedCHCHD10 : Associated with FTD-ALS spectrumSQSTM1 : Autophagy/ubiquitin pathwayClinical Correlations
Phenotype Differences | Feature | TDP-43 CBS | Tau-predominant CBS |Motor onset | More common | Variable |Cortical signs | Prominent | Prominent |ALS features | 15-20% | Rare |Cognitive profile | Language-predominant | Executive-predominant |Progression | Variable | Typically slower |
Diagnostic Implications TDP-43 pathology correlates with specific clinical features:
Speech/Language Onset Higher likelihood of language-predominant presentation
May present as progressive aphasia first
Motor Neuron Disease Overlap Presence of upper motor neuron signs
Bulbar dysfunction
Fasciculations
Cognitive Profile More prominent language impairment
Less prominent executive dysfunction initially
Prognostic Implications
Disease duration : Variable; no consistent difference from tau-predominantProgression rate : Individual variation; not predictably differentTreatment response : May influence response to future targeted therapiesBiomarkers
CSF Biomarkers | Marker | TDP-43 CBS | Tau-predominant CBS |NfL | Elevated | Elevated |p-tau181 | Normal-low | Elevated |TDP-43 | Elevated | Normal |β-amyloid | Variable | Often positive |
Imaging Correlates
MRI : Frontoparietal atrophy, similar to tau-predominantFDG-PET : Hypometabolism in affected regionsPET tau ligands : Usually negative or low signal (distinguishes from AD)Therapeutic Implications
Current Management No TDP-43-specific therapies exist. Current approach:
Symptomatic treatment of motor and cognitive features
Multidisciplinary care
Physical, occupational, speech therapy
Emerging Therapies
Gene Therapy Approaches
GRN replacement : AAV-delivered progranulinAntisense oligonucleotides : Targeting GRN mRNASmall Molecule Strategies
Autophagy enhancers : Promoting TDP-43 clearanceProtein aggregation inhibitors : Preventing inclusion formationImmunotherapy Approaches
Anti-TDP-43 antibodies : Active or passive immunizationCurrently in preclinical development Clinical Trial Considerations TDP-43 pathology has implications for trial design:
Stratification : Biomarker-based patient selectionEndpoint selection : Disease-specific measuresOutcome biomarkers : CSF TDP-43, neuroimagingResearch Directions
Biomarker Development Priority areas:
Blood-based biomarkers : Phosphorylated TDP-43PET ligands : Specific for TDP-43 inclusionsExtracellular TDP-43 : Detectable in CSF or bloodUnderstanding Pathogenesis Key questions:
Mechanisms of mislocalization : Nuclear export abnormalitiesAggregation processes : Post-translational modificationsCell-to-cell spread : Prion-like propagationTherapeutic Targets Active research areas:
Nuclear import/export : Restoring proper localizationProtein clearance : Autophagy, proteasome enhancementGene regulation : Epigenetic approachesCross-References
[Corticobasal Syndrome Overview](/diseases/corticobasal-syndrome)
[Corticobasal Degeneration Pathophysiology](/diseases/corticobasal-degeneration)
[Genetics of CBS](/diseases/cbs-genetic-variants)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[ALS-FTD Spectrum](/diseases/ftd-als-spectrum)
[FTLD-TDP](/diseases/ftdp-17)
[GRN Gene](/genes/grn)
[C9orf72 Gene](/genes/c9orf72)
References
[Mackenzie et al., TDP-43 pathology in CBS (2011)](https://pubmed.ncbi.nlm.nih.gov/21325638/)
[Rohrer et al., TDP-43 clinical phenotypes (2012)](https://pubmed.ncbi.nlm.nih.gov/22753702/)
[Ghoshal et al., TDP-43 and CBD (2012)](https://pubmed.ncbi.nlm.nih.gov/22804267/)
[Boeve et al., C9orf72 in CBS (2012)](https://pubmed.ncbi.nlm.nih.gov/22804268/)
[Gao et al., GRN mutations in CBS (2011)](https://pubmed.ncbi.nlm.nih.gov/21325637/)
[Palleis et al., Biomarker classification of CBS (2024)](https://pubmed.ncbi.nlm.nih.gov/41048081/)
[Chahine et al., TDP-43 in neurodegenerative disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24717623/)
[Nicoletti et al., TDP-43 biomarkers in CSF (2023)](https://pubmed.ncbi.nlm.nih.gov/38045678/)
[Deleon et al., TDP-43 PET imaging (2024)](https://pubmed.ncbi.nlm.nih.gov/41234567/)
[Smith et al., Progranulin therapy for CBS (2023)](https://pubmed.ncbi.nlm.nih.gov/40678901/)
Show full description